Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial

Abstract Background More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within 2 years. This recurrence rate emphasises the need for improved treatment and patient selection. In line with the treatment of...

Cijeli opis

Bibliografski detalji

Glavni autori:	J. Janssen, F. H. E. Staal, C. L. Brouwer, J. A. Langendijk, I. J. de Jong, R. J. A. van Moorselaar, E. Schuit, J. F. Verzijlbergen, R. J. Smeenk, S. Aluwini
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2022-05-01
Serija:	BMC Cancer
Teme:	Oligometastasis Recurrence Prostate Cancer MDRT SBRT ADT
Online pristup:	https://doi.org/10.1186/s12885-022-09523-2
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!